These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 23250418)

  • 1. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors.
    Yu W; Chory EJ; Wernimont AK; Tempel W; Scopton A; Federation A; Marineau JJ; Qi J; Barsyte-Lovejoy D; Yi J; Marcellus R; Iacob RE; Engen JR; Griffin C; Aman A; Wienholds E; Li F; Pineda J; Estiu G; Shatseva T; Hajian T; Al-Awar R; Dick JE; Vedadi M; Brown PJ; Arrowsmith CH; Bradner JE; Schapira M
    Nat Commun; 2012; 3():1288. PubMed ID: 23250418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of Wnt signaling target gene expression by the histone methyltransferase DOT1L.
    Gibbons GS; Owens SR; Fearon ER; Nikolovska-Coleska Z
    ACS Chem Biol; 2015 Jan; 10(1):109-14. PubMed ID: 25361163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L.
    Anglin JL; Deng L; Yao Y; Cai G; Liu Z; Jiang H; Cheng G; Chen P; Dong S; Song Y
    J Med Chem; 2012 Sep; 55(18):8066-74. PubMed ID: 22924785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.
    Deshpande AJ; Chen L; Fazio M; Sinha AU; Bernt KM; Banka D; Dias S; Chang J; Olhava EJ; Daigle SR; Richon VM; Pollock RM; Armstrong SA
    Blood; 2013 Mar; 121(13):2533-41. PubMed ID: 23361907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-guided DOT1L probe optimization by label-free ligand displacement.
    Yi JS; Federation AJ; Qi J; Dhe-Paganon S; Hadler M; Xu X; St Pierre R; Varca AC; Wu L; Marineau JJ; Smith WB; Souza A; Chory EJ; Armstrong SA; Bradner JE
    ACS Chem Biol; 2015 Mar; 10(3):667-74. PubMed ID: 25397901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of potent DOT1L inhibitors by AlphaLISA based High Throughput Screening assay.
    Song Y; Li L; Chen Y; Liu J; Xiao S; Lian F; Zhang N; Ding H; Zhang Y; Chen K; Jiang H; Zhang C; Liu YC; Chen S; Luo C
    Bioorg Med Chem; 2018 May; 26(8):1751-1758. PubMed ID: 29534934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DOT1L inhibitor improves early development of porcine somatic cell nuclear transfer embryos.
    Tao J; Zhang Y; Zuo X; Hong R; Li H; Liu X; Huang W; Cao Z; Zhang Y
    PLoS One; 2017; 12(6):e0179436. PubMed ID: 28632762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.
    Daigle SR; Olhava EJ; Therkelsen CA; Majer CR; Sneeringer CJ; Song J; Johnston LD; Scott MP; Smith JJ; Xiao Y; Jin L; Kuntz KW; Chesworth R; Moyer MP; Bernt KM; Tseng JC; Kung AL; Armstrong SA; Copeland RA; Richon VM; Pollock RM
    Cancer Cell; 2011 Jul; 20(1):53-65. PubMed ID: 21741596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro.
    Sarkaria SM; Christopher MJ; Klco JM; Ley TJ
    Leukemia; 2014 Dec; 28(12):2403-6. PubMed ID: 25092143
    [No Abstract]   [Full Text] [Related]  

  • 10. Bromo-deaza-SAH: a potent and selective DOT1L inhibitor.
    Yu W; Smil D; Li F; Tempel W; Fedorov O; Nguyen KT; Bolshan Y; Al-Awar R; Knapp S; Arrowsmith CH; Vedadi M; Brown PJ; Schapira M
    Bioorg Med Chem; 2013 Apr; 21(7):1787-1794. PubMed ID: 23433670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Novel Disruptor of Telomeric Silencing 1-like (DOT1L) Inhibitors through Structure-Based Virtual Screening and Biological Assays.
    Chen S; Li L; Chen Y; Hu J; Liu J; Liu YC; Liu R; Zhang Y; Meng F; Zhu K; Lu J; Zheng M; Chen K; Zhang J; Jiang H; Yao Z; Luo C
    J Chem Inf Model; 2016 Mar; 56(3):527-34. PubMed ID: 26914852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia.
    Barve A; Vega A; Shah PP; Ghare S; Casson L; Wunderlich M; Siskind LJ; Beverly LJ
    Cells; 2019 Oct; 8(11):. PubMed ID: 31717699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer.
    Zhang L; Deng L; Chen F; Yao Y; Wu B; Wei L; Mo Q; Song Y
    Oncotarget; 2014 Nov; 5(21):10665-77. PubMed ID: 25359765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Novel Disruptor of Silencing Telomeric 1-Like (DOT1L) Inhibitors using a Target-Specific Scoring Function for the (S)-Adenosyl-l-methionine (SAM)-Dependent Methyltransferase Family.
    Wang Y; Li L; Zhang B; Xing J; Chen S; Wan W; Song Y; Jiang H; Jiang H; Luo C; Zheng M
    J Med Chem; 2017 Mar; 60(5):2026-2036. PubMed ID: 28165739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L.
    Anglin JL; Song Y
    J Med Chem; 2013 Nov; 56(22):8972-83. PubMed ID: 23879463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computer-Aided Discovery of Massonianoside B as a Novel Selective DOT1L Inhibitor.
    Chen J; Park HJ
    ACS Chem Biol; 2019 May; 14(5):873-881. PubMed ID: 30951287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l.
    Chen L; Deshpande AJ; Banka D; Bernt KM; Dias S; Buske C; Olhava EJ; Daigle SR; Richon VM; Pollock RM; Armstrong SA
    Leukemia; 2013 Apr; 27(4):813-22. PubMed ID: 23138183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
    Khirsariya P; Pospíšil P; Maier L; Boudný M; Babáš M; Kroutil O; Mráz M; Vácha R; Paruch K
    J Med Chem; 2022 Apr; 65(7):5701-5723. PubMed ID: 35302777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
    Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
    Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mixed lineage rearranged leukaemia: pathogenesis and targeting DOT1L.
    Stein EM; Tallman MS
    Curr Opin Hematol; 2015 Mar; 22(2):92-6. PubMed ID: 25635757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.